Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Compugen aims at predictive drug discovery
December 2006
SHARING OPTIONS:

COLD SPRING HARBOR, N.Y.—Compugen announced at the 2006 Cold Spring Harbor Meeting on Pharmacogenomics the launch of its GeneVa structural genomic variations platform, providing predicted non-SNP, medium- and large-scale genetic variations in the human genome.
 
The important role of such varia­tions has recently become increas­ingly apparent, the company says, noting that SNPs are genomic loca­tions where a single nucleotide can differ between individuals. Due to their high frequency in the human genome, a large number of tech­niques are used today to exploit SNP information for genotyping efforts.
 
Recent reports show that medium- and large-scale inser­tions and deletions are also a sub­stantial source of polymorphism in humans and it is expected they will facilitate theranostic and dis­ease predisposition studies with a higher degree of success than cur­rent SNP-only approaches.
 
The GeneVa platform currently incorporates a database, developed during the past year, of approxi­mately 200,000 novel predicted insertions, deletions and copy-number variations in the human genome. This database was cre­ated by analyzing genomic, EST (expressed sequence tag), disease-related and other databases.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.